UNSPSC 51291705: Fenpentadiol

This classification denotes an antidepressant agent with the molecular formula C12H17CLO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, BLO7300903 chemically known as 2-(p-chlorophenyl)-4-methyl-2,4-pentanediol but generally known as fenpentadiol, which bears US NIH Compound Identifier 85896. European Medicines Agency schedules Fenpentadiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07585MIG.

UNSPSC 51291705 Fenpentadiol, a Commodity code, shows minimal direct match with recent state and local procurement activity under its nominal designation. The three most recent opportunities posted under or near this code—Seminole County's naloxone and drug deactivation systems procurement, the Texas Health and Human Services Commission's therapeutic pharmacy initiative RFI, and MMCAP's generic pharmaceuticals and OTC products RFP—involve finished pharmaceutical products and pharmacy benefit management rather than fenpentadiol as a raw chemical or excipient. Seminole County is procuring naloxone units and safe drug deactivation systems for community health delivery, while Texas HHS is gathering market intelligence on direct-to-manufacturer prescription fulfillment models, and MMCAP (administered by the Minnesota Department of Administration) is establishing statewide and multi-state cooperative contracts for generic drugs and OTC products distributed through authorized wholesalers. The issuing bodies span county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Activity under this code appears concentrated in three states—Florida (Seminole County's IFB60459723LAS, due July 26, 2023), Texas (HHS RFI HHS0017013, posted April 3, 2026), and Minnesota (MMCAP RFP S1070000015802, due March 26, 2026)—though the MMCAP vehicle extends to Oregon and other participating members. The Seminole County opportunity requires quarterly delivery of naloxone and drug deactivation systems with electronic bidding and E-Verify compliance; the Texas RFI is exploratory, gathering vendor capability and market data before formal RFP issuance; and the MMCAP RFP establishes multi-award contracts with effective date July 1, 2026, requiring compliance with cGMP and DSCSA certification, EDI capability, and pricing through authorized wholesalers. The mismatch between the code's nominal chemical designation and the finished-product pharmaceutical and pharmacy-operations scope of these solicitations suggests the code may see limited direct relevance for fenpentadiol as a standalone commodity in recent state and local procurement.